A new study published in the journal Brain reveals that increasing levels of a key brain protein might help slow cognitive ...

Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been ...

The Emory Goizueta Brain Health Institute (GBHI) has prioritized involving African American volunteers in its research, ...

LIFT-AD trial did not meet primary endpoint of GST and key secondary endpoints of cognition (ADAS-Cog11) and function ...

A study published in the journal Brain shows that increases in protein levels with new Alzheimer's drugs can explain the ...

New research suggests that the lessening of amyloid-beta in the brain is behind cognitive decline in Alzheimer's and boosting ...

A study shows that rising levels of brain protein Aβ42, not the reduction of amyloid plaques, better explains the cognitive ...

Leqembi and Kisunla don’t just reduce amyloid plaques that are implicated in Alzheimer’s disease. According to new research, ...

"Aβ42 is a protein that defends our brain from a variety of toxic and infectious exposures," Espay said. "In the process of reacting, it transforms into amyloid plaques. Amyloid plaques is made of ...

A study published Wednesday in Nature Neuroscience sheds light into how amyloid-beta and tau proteins impact brain activity ...

Boosting a certain brain protein could help slow the progression of Alzheimer’s disease, a new study has found. The ...

Caffeine and Alzheimer disease risk appear to be linked, as lower caffeine intake is associated with Alzheimer disease biomarkers.